We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer's Hemophilia B Gene Therapy Candidate Enters Phase III
Read MoreHide Full Article
Pfizer Inc. (PFE - Free Report) announced that it initiated a phase III, lead-in study of an experimental gene therapy treatment, fidanacogene elaparvovec, for patients with hemophilia B. Fidanacogene elaparvovec, a high-activity human coagulation factor IX gene, is a one-time treatment option.
Pfizer also plans to conduct the next part of the phase III study and the patients who completeat least six months in the lead-in studywill be moved to this pivotal study. Fidanacogene elaparvovec was previously known as SPK-9001/PF-06838435 and was originally developed by Spark Therapeutics . Fidanacogene elaparvovec was transferred by Spark to Pfizer, following positive results announced from an ongoing phase I/II study in May 2018.
The results showed that all 15 patients in the study were able to discontinue routine infusions of factor IX concentrates with no reported serious adverse or thrombotic events. Consequently, Pfizer has now assumed sole responsibility for all subsequent pivotal studies, and regulatory and development activities of any product, resulting from the hemophilia B gene therapy program
Hemophilia B is a rare, genetic bleeding disorder found almost exclusively in males. It causes the blood to take a long time to clot because of a deficiency in one of several blood clotting factors, most notably clotting factor IX, a specific protein in the blood. It is expected that hemophilia B patients if once treated with fidanacogene elaparvovec will be able to produce factor IX themselves, rather than having to regularly inject factor IX.
Year to date, shares of Pfizer have increased 3.7% compared with the industry’s decline of 1.7%.
Gene therapy is set to become one of the most promising space in the volatile biotech sector, which continues to grapple with increasing threat from biosimilars.
Pfizer is also developing other candidates for gene therapy.The company’s mini-dystrophin gene therapy candidate, PF-06939926 is in phase Ib clinical trial, being evaluated in boys with duchenne muscular dystrophy.
We remind investors that Spark, in December 2017, obtained the FDA approval for its lead gene therapy drug, Luxturna (voretigene neparvovec-rzyl), for the treatment of patients with viable retinal cells and confirmed biallelic RPE65 mutation-associated retinal dystrophy.
Luxturna is the first FDA-approved gene therapy for inherited retinal disease and the first adeno-associated virus (AAV) vector gene therapy approved United States. The company has built a pipeline of gene therapy candidates that are directed to the retina, the liver and the central nervous system.
The pipeline includes an ocular program consisting of SPK-7001, targeting choroideremia, currently in phase I/II clinical trials. Its hemophilia programs also consist of SPK-8011 for hemophilia A, currently in phase I/II clinical trials.
BioMarin Pharmaceutical (BMRN - Free Report) is also developing valoctocogene roxaparvovec, an experimental gene therapy for the treatment of patients with severe hemophilia.
uniQure N.V. is another promising player in this space, which is creating a pipeline of innovative gene therapies that have been developed both internally and through its collaboration with Bristol Myers-Squibb (BMY - Free Report) .
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6% and +67.1%. And this outperformance has not just been a recent phenomenon.
Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Pfizer's Hemophilia B Gene Therapy Candidate Enters Phase III
Pfizer Inc. (PFE - Free Report) announced that it initiated a phase III, lead-in study of an experimental gene therapy treatment, fidanacogene elaparvovec, for patients with hemophilia B. Fidanacogene elaparvovec, a high-activity human coagulation factor IX gene, is a one-time treatment option.
Pfizer also plans to conduct the next part of the phase III study and the patients who completeat least six months in the lead-in studywill be moved to this pivotal study. Fidanacogene elaparvovec was previously known as SPK-9001/PF-06838435 and was originally developed by Spark Therapeutics . Fidanacogene elaparvovec was transferred by Spark to Pfizer, following positive results announced from an ongoing phase I/II study in May 2018.
The results showed that all 15 patients in the study were able to discontinue routine infusions of factor IX concentrates with no reported serious adverse or thrombotic events. Consequently, Pfizer has now assumed sole responsibility for all subsequent pivotal studies, and regulatory and development activities of any product, resulting from the hemophilia B gene therapy program
Hemophilia B is a rare, genetic bleeding disorder found almost exclusively in males. It causes the blood to take a long time to clot because of a deficiency in one of several blood clotting factors, most notably clotting factor IX, a specific protein in the blood. It is expected that hemophilia B patients if once treated with fidanacogene elaparvovec will be able to produce factor IX themselves, rather than having to regularly inject factor IX.
Year to date, shares of Pfizer have increased 3.7% compared with the industry’s decline of 1.7%.
Gene therapy is set to become one of the most promising space in the volatile biotech sector, which continues to grapple with increasing threat from biosimilars.
Pfizer is also developing other candidates for gene therapy.The company’s mini-dystrophin gene therapy candidate, PF-06939926 is in phase Ib clinical trial, being evaluated in boys with duchenne muscular dystrophy.
We remind investors that Spark, in December 2017, obtained the FDA approval for its lead gene therapy drug, Luxturna (voretigene neparvovec-rzyl), for the treatment of patients with viable retinal cells and confirmed biallelic RPE65 mutation-associated retinal dystrophy.
Luxturna is the first FDA-approved gene therapy for inherited retinal disease and the first adeno-associated virus (AAV) vector gene therapy approved United States. The company has built a pipeline of gene therapy candidates that are directed to the retina, the liver and the central nervous system.
The pipeline includes an ocular program consisting of SPK-7001, targeting choroideremia, currently in phase I/II clinical trials. Its hemophilia programs also consist of SPK-8011 for hemophilia A, currently in phase I/II clinical trials.
BioMarin Pharmaceutical (BMRN - Free Report) is also developing valoctocogene roxaparvovec, an experimental gene therapy for the treatment of patients with severe hemophilia.
uniQure N.V. is another promising player in this space, which is creating a pipeline of innovative gene therapies that have been developed both internally and through its collaboration with Bristol Myers-Squibb (BMY - Free Report) .
Pfizer Inc. Price
Pfizer Inc. Price | Pfizer Inc. Quote
Zacks Rank & Stocks to Consider
Pfizer has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank stocks here.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6% and +67.1%. And this outperformance has not just been a recent phenomenon.
Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>